PubMed · 2008 · 35 citations · 10 references
MedicinePharmacologyClinical PharmacologyHepatic PharmacokineticsHepatic PharmacotherapyAcute Liver FailureHepatic EncephalopathyHepatic Encephalopathy TreatmentCirrhosis-related EncephalopathyDietary Protein IntakeHepatic Encephalopathy ManagementL-ornithine L-aspartate TherapyOvert Hepatic EncephalopathyPlacebo ComparatorsPlacebo-controlled Efficacy AssessmentSerum Aspartate Aminotransferase
OBJECTIVE: To determine the efficacy of L-ornithine-L-aspartate in treatment of hepatic encephalopathy. STUDY DESIGN: Randomized, placebo-controlled trial. PLACE AND DURATION OF STUDY: Department of Gastroenterology and Hepatology, Sheikh Zayed Hospital, Lahore, from February to August 2005. METHODOLOGY: Cirrhotic patients with hyperammonemia and overt hepatic encephalopathy were enrolled. Eighty patients were randomized to two treatment groups, L-ornithine-L-aspartate (20 g/d) or placebo, both dissolved in 250 mL of 5% dextrose water and infused intravenously for four hours a day for five consecutive days with 0.5 g/kg dietary protein intake at the end of daily treatment period. Outcome variables were postprandial blood ammonia and mental state grade. Adverse reactions and mortality were also determined. RESULTS: Both treatment groups were comparable regarding age, gender, etiology of cirrhosis, Child-Pugh class, mental state grade and blood ammonia at baseline. Although, improvement occurred in both groups, there was a greater improvement in L-ornithine-L-aspartate group with regard to both variables. Four patients in the placebo group and 2 in L-ornithine-L-aspartate group died. CONCLUSION: L-ornithine-L-aspartate infusions were found to be effective in cirrhotic patients with hepatic encephalopathy.
10
Manganese and chronic hepatic encephalopathy
Derk Krieger, Silke Krieger, Lorenz Theilmann et al. · The Lancet · 1995 · 442 citations